Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer

  • Authors:
    • Yiran Wang
    • Ying Wang
    • Ning Wang
    • Lifang You
    • Fei Long
    • Changjuan Shao
    • Yajie Wang
    • Jiaxue Wu
  • View Affiliations

  • Published online on: July 18, 2019     https://doi.org/10.3892/or.2019.7242
  • Pages: 1467-1474
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

With the increasing use of poly(ADP‑ribose) polymerase (PARP) inhibitors in cancer therapy, understanding their resistance is an urgent research quest. Additionally, CHFR is an E3 ubiquitin ligase, recruited to double‑strand breaks (DSBs) by PAR. Furthermore, ALC1 is a new oncogene involved in the invasion and metastasis of breast cancer. Moreover, PARylated PARP1 activates ALC1 at sites of DNA damage, yet the underlying mechanism remains unclear. Mass spectrometric analysis, western blot analysis and immunoprecipitation were performed to confirm the interaction between CHFR and ALC1 in the physiological condition. Deletion mutants of CHFR and ALC1 were generated to map the interaction domain. PARP1/2 inhibitors were added to identify the ubiquitination of ALC1 by CHFR. ALC1 half‑life was examined to compare the expression of ALC1 protein in the presence and absence of PARP1/2 inhibitors. The results revealed that the transcriptional level of ALC1 was not upregulated in breast cancer tissues. CHFR interacted with ALC1. The PBZ domain of CHFR, the PMD domain and the MACRO domain of ALC1 domain are the necessary regions for the interaction depending on PAR. Ubiquitination of ALC1 by CHFR was dependent on PARylation and resulted in the degradation of PARylated ALC1. PARP1/2 inhibitors decreased the ubiquitination of PAR‑dependent ALC1, and the expression of ALC1 was upregulated by PARP1/2 inhibitors. Ubiquitination mediated by CHFR resulted in the degradation of ALC1. In conclusion, PARP1/2 inhibitors decrease the ubiquitination of ALC1 leading to the accumulation of ALC1, which affects the therapeutic effects of DNA damage response drugs in breast cancer treatment.

References

1 

Kolb AL, Gunn AR and Lakin ND: Redundancy between nucleases required for homologous recombination promotes PARP inhibitor resistance in the eukaryotic model organism Dictyostelium. Nucleic Acids Res. 45:10056–10067. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB and Hoogerbrugge N: High satisfaction and low distress in breast cancer patients one year after BRCA-mutation testing without prior Face-to-Face genetic counseling. J Genet Couns. 25:504–514. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, et al: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 114:723–730. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Kulkarni A, Oza J, Yao M, Sohail H, Ginjala V, Tomas-Loba A, Horejsi Z, Tan AR, Boulton SJ and Ganesan S: Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with amplified in liver cancer 1 (ALC1) protein. J Biol Chem. 288:32357–32369. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Rugo HS, Olopade OI, DeMichele A, Yau C, van't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, et al: Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 375:23–34. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, et al: Niraparib maintenance therapy in Platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 375:2154–2164. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Sellou H, Lebeaupin T, Chapuis C, Smith R, Hegele A, Singh HR, Kozlowski M, Bultmann S, Ladurner AG, Timinszky G, et al: The poly(ADP-ribose)-dependent chromatin remodeler Alc1 induces local chromatin relaxation upon DNA damage. Mol Biol Cell. 27:3791–3799. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Ahel D, Horejsi Z, Wiechens N, Polo SE, Garcia-Wilson E, Ahel I, Flynn H, Skehel M, West SC, Jackson SP, et al: Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science. 325:1240–1243. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Wu J, Zong Y, Fei X, Chen X, Huang O, He J, Chen W, Li Y, Shen K and Zhu L: Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer. PLoS One. 9:e986732014. View Article : Google Scholar : PubMed/NCBI

11 

Xu X, He Y, Miao X, Wu Y, Han J, Wang Q, Liu J, Zhong F, Ou Y, Wang Y and He S: Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells. Leuk Res. 47:54–62. 2016. View Article : Google Scholar : PubMed/NCBI

12 

He LR, Ma NF, Chen JW, Li BK, Guan XY, Liu MZ and Xie D: Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. Oncotarget. 6:31181–31190. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Mu QJ, Li HL, Yao Y, Liu SC, Yin CG and Ma XZ: Chromodomain Helicase/ATPase DNA-binding protein 1-Like Gene (CHD1L) expression and implications for invasion and metastasis of breast cancer. PLoS One. 10:e01430302015. View Article : Google Scholar : PubMed/NCBI

14 

Tsuda M, Cho K, Ooka M, Shimizu N, Watanabe R, Yasui A, Nakazawa Y, Ogi T, Harada H, Agama K, et al: ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair. PLoS One. 12:e01883202017. View Article : Google Scholar : PubMed/NCBI

15 

Jiang BH, Chen WY, Li HY, Chien Y, Chang WC, Hsieh PC, Wu P, Chen CY, Song HY, Chien CS, et al: CHD1L regulated PARP1-driven pluripotency and chromatin remodeling during the early-stage cell reprogramming. Stem Cells. 33:2961–2972. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Lehmann LC, Hewitt G, Aibara S, Leitner A, Marklund E, Maslen SL, Maturi V, Chen Y, van der Spoel D, Skehel JM, et al: Mechanistic insights into autoinhibition of the oncogenic chromatin remodeler ALC1. Mol Cell. 68:847–859.e7. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Sun Z, Liu J, Jing H, Dong SX and Wu J: The diagnostic and prognostic value of CHFR hypermethylation in colorectal cancer, a meta-analysis and literature review. Oncotarget. 8:89142–89148. 2017.PubMed/NCBI

18 

Privette LM, Gonzalez ME, Ding L, Kleer CG and Petty EM: Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: Implications for tumor suppression. Cancer Res. 67:6064–6074. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Kashima L, Idogawa M, Mita H, Shitashige M, Yamada T, Ogi K, Suzuki H, Toyota M, Ariga H, Sasaki Y and Tokino T: CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation. J Biol Chem. 287:12975–12984. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Brodie SA, Li G, Donald H, Khuri FR, Vertino PM and Brandes JC: Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer. Oncotarget. 6:30773–30786. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Lim JS and Tan DS: Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors. Cancers (Basel). 9:E1092017. View Article : Google Scholar : PubMed/NCBI

22 

Luijsterburg MS, de Krijger I, Wiegant WW, Shah RG, Smeenk G, de Groot AJ, Pines A, Vertegaal AC, Jacobs JJ, Shah GM and van Attikum H: PARP1 Links CHD2-mediated chromatin expansion and H3.3 deposition to DNA Repair by Non-homologous End-Joining. Molecular Cell. 61:547–562. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Rajawat J, Shukla N and Mishra DP: Therapeutic targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in cancer: Current developments, therapeutic strategies, and future opportunities. Med Res Rev. 37:1461–1491. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, et al: Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 229:422–429. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Wang YT, Yuan B, Chen HD, Xu L, Tian YN, Zhang A, He JX and Miao ZH: Acquired resistance of PTEN-deficient cells to PARP inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression. Cancer Sci. 109:821–831. 2018. View Article : Google Scholar : PubMed/NCBI

26 

Singh HR, Nardozza AP, Möller IR, Knobloch G, Kistemaker HA, Hassler M, Harrer N, Blessing C, Eustermann S, Kotthoff C, et al: A Poly-ADP-Ribose trigger releases the Auto-inhibition of a chromatin remodeling oncogene. Mol Cell. 68:860–871.e7. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Kim M, Kwon YE, Song JO, Bae SJ and Seol JH: CHFR negatively regulates SIRT1 activity upon oxidative stress. Sci Rep. 6:375782016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 42 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, Y., Wang, Y., Wang, N., You, L., Long, F., Shao, C. ... Wu, J. (2019). Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer. Oncology Reports, 42, 1467-1474. https://doi.org/10.3892/or.2019.7242
MLA
Wang, Y., Wang, Y., Wang, N., You, L., Long, F., Shao, C., Wang, Y., Wu, J."Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer". Oncology Reports 42.4 (2019): 1467-1474.
Chicago
Wang, Y., Wang, Y., Wang, N., You, L., Long, F., Shao, C., Wang, Y., Wu, J."Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer". Oncology Reports 42, no. 4 (2019): 1467-1474. https://doi.org/10.3892/or.2019.7242